Enfortumab vedotin plus pembrolizumab improved EFS, OS, and pCR rates in MIBC patients ineligible for cisplatin-based chemotherapy. The combination therapy showed a median EFS and OS that were not ...
- Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including ...
Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of ...
Overall survival (OS) data, published simultaneously by the Journal of Clinical Oncology, 2 show the longest survival data ever seen in these patients, who typically were treated with chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback